# H19 Is a PERK-Regulated Long Non-Coding RNA That Fine-Tunes UPR Signalling and Inhibits Endoplasmic Reticulum Stress-Induced Cell Death

**Authors:** Wen Liu, Ananya Gupta, Michael Kerin, Sanjeev Gupta

PMC · DOI: 10.3390/ijms27041658 · International Journal of Molecular Sciences · 2026-02-08

## TL;DR

The lncRNA H19 is regulated by PERK during ER stress and helps control cell survival by modulating UPR signaling.

## Contribution

H19 is identified as a novel PERK-regulated lncRNA that modulates UPR signaling and cell fate during ER stress.

## Key findings

- H19 expression is downregulated during ER stress in a PERK-dependent manner.
- H19 overexpression enhances ATF6 and PERK signaling while reducing IRE1-XBP1 activity.
- High H19 levels correlate with poor prognosis in basal-like breast cancer.

## Abstract

The endoplasmic reticulum (ER) responds to stimuli that disrupts its homeostasis by activating a signalling network known as unfolded protein response (UPR), that restores cellular balance and determines cell fate through three key sensors: inositol-requiring enzyme 1α (IRE1α), activating transcription factor 6 (ATF6), and protein kinase RNA-like ER kinase (PERK). Emerging evidence suggests that UPR regulates the expression of numerous long non-coding RNAs (lncRNAs), which play critical roles in maintaining ER homeostasis. Here we show that expression of lncRNA H19 is downregulated in response to ER stress in (MCF7, T47D and 293T) cells. Using genetic and pharmacological approaches, we demonstrate that H19 downregulation is primarily mediated by the PERK arm of the UPR. Specifically, knockdown or chemical inhibition of PERK compromised the ER stress-mediated H19 repression, while PERK activation significantly reduced H19 expression. H19 overexpression promotes the optimal activation of ATF6 and PERK pathways, while it attenuates the signalling by IRE1-XBP1 axis of the UPR. Furthermore, in triple-negative breast cancer (TNBC) cells MDA-MB-231, ectopic H19 provided resistance to ER stress-induced apoptosis. Bioinformatic analyses across multiple breast cancer cohorts revealed that high H19 expression was associated with poor prognosis, particularly in basal-like subtypes. Collectively, our findings show that H19 is downregulated during UPR in a PERK-dependent manner, where H19 in turn modulates UPR signalling and cell fate during conditions of ER stress.

## Linked entities

- **Genes:** H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120], ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081], ATF6 (activating transcription factor 6) [NCBI Gene 22926], EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451]
- **Diseases:** breast cancer (MONDO:0004989), triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, DNAJB9 (DnaJ heat shock protein family (Hsp40) member B9) [NCBI Gene 4189] {aka ERdj4, MDG-1, MDG1, MST049, MSTP049}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, VDAC1 (voltage dependent anion channel 1) [NCBI Gene 7416] {aka PORIN, VDAC-1}, ATF6 (activating transcription factor 6) [NCBI Gene 530610], MIR675 (microRNA 675) [NCBI Gene 100033819] {aka MIRN675, hsa-mir-675}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, GOLGA2P10 (GOLGA2 pseudogene 10) [NCBI Gene 80154], EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, XBP1 (X-box binding protein 1) [NCBI Gene 541236] {aka XBPP1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, MBD1 (methyl-CpG binding domain protein 1) [NCBI Gene 4152] {aka CXXC3, PCM1, RFT}, MALAT1 (metastasis associated lung adenocarcinoma transcript 1) [NCBI Gene 378938] {aka HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, miPEP-52}, MLRL (Myeloid leukemia-related gene (myeloid tumor suppressor)) [NCBI Gene 8201] {aka MLRG, MTS}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, H19 (H19, imprinted maternally expressed transcript (non-protein coding)) [NCBI Gene 100126192], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, SEC24D (SEC24 homolog D, COPII component) [NCBI Gene 9871] {aka CLCRP2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, KCNIP3 (potassium voltage-gated channel interacting protein 3) [NCBI Gene 30818] {aka CSEN, DREAM, KCHIP3}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, HERPUD1 (homocysteine inducible ER protein with ubiquitin like domain 1) [NCBI Gene 9709] {aka HERP, HERPUD1-IT1, Mif1, SUP}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR6753 (microRNA 6753) [NCBI Gene 102465451] {aka hsa-mir-6753}, MIR6755 (microRNA 6755) [NCBI Gene 102465452] {aka hsa-mir-6755}, BCL2L11 (BCL2 like 11) [NCBI Gene 10018] {aka BAM, BIM, BOD}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, RPLP0 (ribosomal protein lateral stalk subunit P0) [NCBI Gene 6175] {aka L10E, LP0, P0, PRLP0, RPP0, uL10}, MIR17HG (miR-17-92a-1 cluster host gene) [NCBI Gene 407975] {aka C13orf25, LINC00048, MIHG1, MIRH1, MIRHG1, NCRNA00048}
- **Diseases:** injury to (MESH:D014947), cardiac, renal and cerebral ischemia (MESH:D002545), cancer (MESH:D009369), tumorigenesis (MESH:D063646), RIDD (MESH:D003731), endocrine resistance (MESH:D004700), chronic pancreatitis (MESH:D050500), TNBC (MESH:D064726), Breast Cancer (MESH:D001943)
- **Chemicals:** 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MESH:C070380), BFA (MESH:D020126), TG (MESH:D019284), NaCl (MESH:D012965), oxygen (MESH:D010100), trastuzumab (MESH:D000068878), streptomycin (MESH:D013307), polyacrylamide (MESH:C016679), PMS (MESH:D008773), resveratrol (MESH:D000077185), SDS (MESH:D012967), PI (MESH:D011419), Ca2+ (-), STF (MESH:C556690), penicillin (MESH:D010406), puromycin (MESH:D011691), GSK (MESH:C576403), CO2 (MESH:D002245), lipid (MESH:D008055), Tween-20 (MESH:D011136), PBS (MESH:D007854), glucose (MESH:D005947), DMSO (MESH:D004121), reactive oxygen species (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MEFs — Mus musculus (Mouse), Finite cell line (CVCL_9115), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), MDA- — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_4747), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), V5 — Homo sapiens (Human), Embryonic stem cell (CVCL_ZJ92), plenti4 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_A1BL), MCF7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), MDA-Ctrl — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_IJ08), MDA-H19 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), BT474 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0179)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941232/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941232/full.md

## References

87 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941232/full.md

---
Source: https://tomesphere.com/paper/PMC12941232